CTOs on the Move

Aporeto

www.aporeto.com

 
Aporeto strengthens security and simplifies operations for enterprises with cloud-native and legacy applications in hybrid and multi-cloud environments by decoupling security from the infrastructure and the network.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aporeto.com
  • 84 W Santa Clara Street Suite 440
    San Jose, CA USA 95113
  • Phone: 866.300.0224

Executives

Name Title Contact Details
Dimitri Stiliadis
Chief Technology Officer Profile

Funding

Aporeto raised $20M on 01/30/2019

Similar Companies

DXC Technology

DXC is the world`s leading independent, end-to-end IT services company, helping clients harness the power of innovation to thrive on change. Created by the merger of CSC and the Enterprise Services business of Hewlett Packard Enterprise, DXC Technology is a $25 billion company with a 60-year legacy of delivering results for thousands of clients in more than 70 countries. Our technology independence, global talent and extensive partner network combine to deliver powerful next-generation IT services and solutions.

Extreme Software

Extreme Software, LLC. is a Broomfield, CO-based company in the Software and Internet sector.

Enklu

Enklu is a U.S.-based leader in spatial computing services, leveraging unique data, an existing content library, and generative AI to offer a profitable licensable package for businesses. With over a million hours of spatial computing experiences delivered and an intelligent platform and ecosystem for creating and delivering content, Enklu provides creators, venues, and home users everything they need for successful and profitable spatial computing experiences

Asolva

Asolva is a Pasadena, CA-based company in the Software and Internet sector.

Vineti

Vineti is a company purpose-built for personalized therapies. From the beginning, Vineti`s founders have understood the challenges that biotech and pharmaceutical innovators face in developing personalized therapies. The emerging ecosystem of cell therapies, gene therapies, and personalized cancer vaccines requires new enabling technologies to align and manage production processes and the patient journey. Our patent pending Personalized Therapy Management (PTM) platform provides the next-generation technology that advanced therapies need.